These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21371635)

  • 1. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines.
    Winchester DE; Wen X; Brearley WD; Park KE; Anderson RD; Bavry AA
    J Am Coll Cardiol; 2011 Mar; 57(10):1190-9. PubMed ID: 21371635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines.
    Winchester DE; Brearley WD; Wen X; Park KE; Bavry AA
    Clin Cardiol; 2012 Feb; 35(2):93-100. PubMed ID: 22028212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
    Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S
    Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
    Shishehbor MH; Topol EJ; Mukherjee D; Hu T; Cohen DJ; Stone GW; McClure R; Roffi M; Moliterno DJ;
    Am J Cardiol; 2006 Jun; 97(11):1585-90. PubMed ID: 16728219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.
    Ndrepepa G; Berger PB; Mehilli J; Seyfarth M; Neumann FJ; Schömig A; Kastrati A
    J Am Coll Cardiol; 2008 Feb; 51(7):690-7. PubMed ID: 18279731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
    Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
    Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
    Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high-risk patients with ST elevation myocardial infarction--a meta-regression of randomized controlled trials.
    Sethi A; Bajaj A; Bahekar A; Bhuriya R; Singh M; Ahmed A; Khosla S
    Catheter Cardiovasc Interv; 2013 Aug; 82(2):171-81. PubMed ID: 22961908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
    Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL
    Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
    Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
    Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of observational studies.
    Kouz R; Kouz S; Schampaert E; Rinfret S; Tardif JC; Nguyen M; Eisenberg M; Harvey R; Afilalo M; Lauzon C; Dery JP; Mansour S; Huynh T
    Int J Cardiol; 2011 Dec; 153(3):249-55. PubMed ID: 20971515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
    Pannu R; Andraws R
    Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction.
    Wang Y; Wu B; Shu X
    Am J Cardiol; 2012 Apr; 109(8):1124-30. PubMed ID: 22245413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.